That's good that you've already made some decent profits it appears and are looking to hedge some of that. I think that's quite wise at this stage.
I appreciate what you're saying, but there are numerous examples where a drug should have worked based on clinical data to date of the drug compared to historical control data for SoC only to see the drug flop in Phase 3. Also, even though it may not appear to make sense on the surface, there's no way to be certain that the later events didn't in fact occur in the BSC arm as opposed to the picoplatin arm. That's why it's so critical to run Phase 2 trials that are controlled. I'm not saying that PARD absolutely will not be successful in the Phase 3 trial, but it's much more ambiguous in the face of no controlled trial where you're relying on historical data to demonstrate the benefit of a given drug.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.